Publicacións en colaboración con investigadores/as de Universidade da Coruña (58)

2022

  1. Analysis of the costs associated with the follow-up of HIV patients discontinuing antiretroviral treatment due to lack of effectiveness or unacceptable toxicity in Spain

    Farmacia Hospitalaria, Vol. 46, Núm. 6, pp. 327-334

  2. Discontinuation due to neuropsychiatric adverse events with efavirenz-and dolutegravir-based antiretroviral therapy: a comparative real-life study

    European Journal of Hospital Pharmacy, Vol. 29, Núm. 4, pp. 207-211

2021

  1. Influence of drug-drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus

    European Journal of Hospital Pharmacy, Vol. 28, Núm. 1, pp. 16-21

2020

  1. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

    Antiviral Research, Vol. 174

  2. Effectiveness and safety of direct-acting antivirals in hepatitis C infected patients with mental disorders: Results in real clinical practice

    Journal of Medical Virology, Vol. 92, Núm. 12, pp. 3488-3498

  3. Epidemiology and outcome of HIV-infected patients admitted to the ICU in the current highly active antiretroviral therapy era

    Medicina Intensiva, Vol. 44, Núm. 5, pp. 283-293

2019

  1. DBP rs16846876 and rs12512631 polymorphisms are associated with progression to AIDS naïve HIV-infected patients: A retrospective study

    Journal of Biomedical Science, Vol. 26, Núm. 1

  2. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis c virus infected patients. Results in real clinical practice

    Revista Espanola de Quimioterapia, Vol. 32, Núm. 2, pp. 137-144

  3. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice-Vie-KinD study

    PLoS ONE, Vol. 14, Núm. 9

  4. Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines

    Journal of the International Association of Providers of AIDS Care, Vol. 18

  5. Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals

    PLoS ONE, Vol. 14, Núm. 6

  6. Predictors of hepatitis C treatment failure after using direct-acting antivirals in people living with human immunodeficiency virus

    Open Forum Infectious Diseases, Vol. 6, Núm. 3

  7. Similar plasma lipidomic profile in people living with HIV treated with a darunavir-based or an integrase inhibitor-based antiretroviral therapy

    Scientific Reports, Vol. 9, Núm. 1

  8. Teleconsultation for the Pharmaceutical Care of HIV Outpatients in Receipt of Home Antiretrovirals Delivery: Clinical, Economic, and Patient-Perceived Quality Analysis

    Telemedicine and e-Health, Vol. 25, Núm. 5, pp. 399-406

  9. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine

    Basic and Clinical Pharmacology and Toxicology, Vol. 124, Núm. 4, pp. 479-490

2018

  1. Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy

    HIV Clinical Trials, Vol. 19, Núm. 5, pp. 197-201

  2. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  3. Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors

    AIDS, Vol. 32, Núm. 1, pp. 121-125

  4. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

  5. Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies

    Journal of Medical Virology, Vol. 90, Núm. 6, pp. 1094-1098